Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of Expanded Haploidentical NK Cells for Leukemia
NCT04327037Phase 1Completed
- Sponsor
- Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
- Start
- Jan 2019
- Primary completion
- Jun 2021
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of expanded haploidentical NK cells in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), sponsored by Belarusian Research Center for Pediatric Oncology, Hematology and Immunology. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 1 month. Started Jan 2019; status: completed.
02
Drugs
expanded haploidentical NK cells
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT04327037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04327037.